CA2207627A1 - 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents - Google Patents

4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents

Info

Publication number
CA2207627A1
CA2207627A1 CA002207627A CA2207627A CA2207627A1 CA 2207627 A1 CA2207627 A1 CA 2207627A1 CA 002207627 A CA002207627 A CA 002207627A CA 2207627 A CA2207627 A CA 2207627A CA 2207627 A1 CA2207627 A1 CA 2207627A1
Authority
CA
Canada
Prior art keywords
alkyl
optionally substituted
sum
heterocycloalkyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002207627A
Other languages
French (fr)
Other versions
CA2207627C (en
Inventor
Wayne D. Vaccaro
John W. Clader
Duane A. Burnett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corporation
Wayne D. Vaccaro
John W. Clader
Duane A. Burnett
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/361,265 external-priority patent/US5656624A/en
Application filed by Schering Corporation, Wayne D. Vaccaro, John W. Clader, Duane A. Burnett filed Critical Schering Corporation
Publication of CA2207627A1 publication Critical patent/CA2207627A1/en
Application granted granted Critical
Publication of CA2207627C publication Critical patent/CA2207627C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Abstract

4-[(Heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinone hypocholesterolemic agents of formula (I) or a pharmaceutically acceptable salt thereof, wherein: A is optionally substituted heterocycloalkyl, optionally substituted heteroaryl, optionally substituted benzofused heterocycloalkyl, or optionally substituted benzofused heteroaryl; Ar1 is optionally substituted aryl; Ar2 is optionally substituted aryl; Q is a bond or, with the 3-position ring carbon of the azetidinone, forms the spiro group (a); and R1 is selected from the group consisting of -(CH2)9-, wherein q is 2-6 provided that when Q is a spiro ring, q can also be 0 or 1;
-(CH2)e-G-(CH2)r, wherein G is -O-, -C(O)-, phenylene, -NR8- or -S(O)0-2-, e is 0-5 and r is 0-5, provided that the sum of a and r is 1-6; alkenylene; and -(CH2)f-V-(CH2)g-, wherein V is cycloalkylene f is 1-5 and g is 0-5, provided that the sum of f and g is 1-6; R5 is (b), (c), (d), (e), (f), (g) or (h); R6 and R7 are -CH2-, -CH(alkyl)-, -C(dialkyl), -CH=CH- or -C(alkyl)=CH-; or R5 together with an adjacent R6, or R5 together with an adjacent R7, form a -CH=CH- or a -CH=C(alkyl)- group; a and b are independently 0-3, provided both are not zero and when Q is a bond Ri also can be: (i), (j) or (k); M is -O- -S- -S(O)- or -S(O)2-;
X, Y and Z are -CH2-, -CH(alkyl)- or -C(dialkyl); R10 and R12 -OR14, -O(CO)R14, -O(CO)OR16 or -O(CO)NR14R15; R11 and R13 are H, alkyl or aryl; or R10 and R11 together are =O, or R12 and R13 together are =O;
d is 1-3; h is 0-4; s is 0 or 1; t is 0 or 1; m, n and p are independently 0-4; provided that at least one of s and t is 1, and the sum of m, n, p, s and t is 1-6; provided that when p is 0 and t is 1, the sum of m, s and n is 1-5; and provided that when p is 0 and s is 1, the sum of m, t and n is 1-5; v is 0 or 1; j and k are independently I-5 provided that the sum of j, k and v is 1-5; Rs is H, alkyl, arylalkyl, -C(O)RI4 or -COOR14; R9 is H, alkyl, alkoxy, -COON, NO2, -NR14R15, OH or halogeno; R14 and R15 are H, alkyl, aryl and arylalkyl; R16 is alkyl or optionally substituted aryl; and R19 is H, OH or alkoxy are disclosed, as well as a method of lowering serum cholesterol by administering said compounds, pharmaceutical compositions containing them, and the combination of a substituted azetidinone and a cholesterol biosynthesis inhibitor for the treatment and prevention of atherosclerosis.
CA002207627A 1994-12-21 1995-12-18 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents Expired - Fee Related CA2207627C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/361,265 US5656624A (en) 1994-12-21 1994-12-21 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
US08/361,265 1994-12-21
PCT/US1995/016007 WO1996019450A1 (en) 1994-12-21 1995-12-18 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents

Publications (2)

Publication Number Publication Date
CA2207627A1 true CA2207627A1 (en) 1996-06-27
CA2207627C CA2207627C (en) 2005-11-15

Family

ID=35530899

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002207627A Expired - Fee Related CA2207627C (en) 1994-12-21 1995-12-18 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents

Country Status (1)

Country Link
CA (1) CA2207627C (en)

Also Published As

Publication number Publication date
CA2207627C (en) 2005-11-15

Similar Documents

Publication Publication Date Title
AU4419896A (en) 4-{(heterocycloalkyl or heteroaromatic)-substituted phenyphenyl}-2-azetidinones useful as hypolipidemic agents
AU669032B2 (en) New indole, indazole and benzisoxazole compounds, process for preparing them and pharmaceutical compositions containing them
HUT69686A (en) Process for preparing pharmaceutical compositions having serum cholesterol lowering effect
EP1036794A4 (en) 2-aryl-8-oxodihydropurine derivatives, process for producing the same, medicinal compositions containing the same, and intermediates thereof
IL102582A0 (en) Substituted beta-lactam compounds useful as hypocholesterolemic agents and processes for the preparation thereof
TW427974B (en) Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
HUT77088A (en) Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents and pharmaceutical compositions containing the same
CA2235943A1 (en) Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
AU3464097A (en) Arylpiperidinol and arylpiperidine derivatives and pharmaceuticals containing the same
CA2238845A1 (en) Novel 2,3,5-trimethyl-4-hydroxy anilide derivatives, preparation thereof and therapeutical use thereof
ATE215937T1 (en) OXAZOLIDINEDIONE DERIVATIVES AND THEIR USE AS HYPOGLYCEMIC AGENTS
CA2207627A1 (en) 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
NZ334736A (en) Acylaminoalkenylene-amide derivatives useful in treatments of the respiratory diseases where it is more specific for NK1 than NK2
WO1999025716A3 (en) Pyranones, method for the production and use thereof
PT955286E (en) D-HYDRO-DERIVATIVES OR TETRA-HYDROFOLANTALINE HAVING AN ESTROGENIC (ANI-) ACTIVITY
IL134551A0 (en) Methods for lowering platelet counts
TW333525B (en) New perhydroisoindole derivatives, their preparation and the pharmaceutical compositions which contain them the invention relates to perhydroisoindole derivatives of general formula (I), and their salts when they exist advantageously as neurokinin A antagonists.
ZA200002151B (en) 1-AZA-2-alkyl-6-aryl-cycloalkane compounds, a process for their preparation and pharmaceutical compositions containing them.
KR910007878A (en) Dihydropyridine Derivatives and Pharmaceutical Compositions
KR970042558A (en) β-methyl carbapenem carboxy ester derivative and preparation method thereof

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20121218